Insider Selling: United Therapeutics Co. (NASDAQ:UTHR) Director Sells $90,721.35 in Stock

United Therapeutics Co. (NASDAQ:UTHR) Director Nilda Mesa sold 255 shares of the company’s stock in a transaction dated Monday, December 30th. The stock was sold at an average price of $355.77, for a total value of $90,721.35. Following the completion of the sale, the director now owns 5,528 shares of the company’s stock, valued at approximately $1,966,696.56. The trade was a 4.41 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Nilda Mesa also recently made the following trade(s):

• On Friday, November 8th, Nilda Mesa sold 224 shares of United Therapeutics stock. The stock was sold at an average price of $412.28, for a total value of $92,350.72.

United Therapeutics Stock Performance

United Therapeutics stock opened at $360.22 on Friday. The stock has a market cap of $16.08 billion, a PE ratio of 15.82, a price-to-earnings-growth ratio of 1.05 and a beta of 0.55. The stock has a 50-day moving average of $370.27 and a two-hundred day moving average of $349.97. United Therapeutics Co. has a one year low of $208.62 and a one year high of $417.82.

United Therapeutics (NASDAQ:UTHR) last released its earnings results on Wednesday, October 30th. The biotechnology company reported $6.39 earnings per share for the quarter, topping the consensus estimate of $6.16 by $0.23. The company had revenue of $748.90 million for the quarter, compared to the consensus estimate of $722.62 million. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. United Therapeutics’s revenue was up 22.9% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $5.38 EPS. As a group, sell-side analysts predict that United Therapeutics Co. will post 25.22 EPS for the current fiscal year.

Wall Street Analyst Weigh In

UTHR has been the topic of a number of analyst reports. LADENBURG THALM/SH SH boosted their price objective on shares of United Therapeutics from $319.00 to $344.00 and gave the company a “buy” rating in a research report on Thursday, October 31st. Jefferies Financial Group raised their price target on United Therapeutics from $315.00 to $432.00 and gave the stock a “buy” rating in a research note on Monday, September 23rd. Argus upped their price objective on United Therapeutics from $360.00 to $400.00 and gave the company a “buy” rating in a research report on Thursday, October 31st. TD Cowen lifted their target price on United Therapeutics from $350.00 to $400.00 and gave the stock a “buy” rating in a research report on Monday, October 21st. Finally, The Goldman Sachs Group upped their target price on shares of United Therapeutics from $243.00 to $302.00 and gave the stock a “neutral” rating in a research note on Friday, November 1st. One analyst has rated the stock with a sell rating, two have issued a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $370.86.

Hedge Funds Weigh In On United Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in UTHR. ClariVest Asset Management LLC boosted its holdings in shares of United Therapeutics by 120.0% in the 2nd quarter. ClariVest Asset Management LLC now owns 77 shares of the biotechnology company’s stock valued at $25,000 after acquiring an additional 42 shares during the last quarter. USA Financial Formulas acquired a new position in United Therapeutics during the third quarter valued at $33,000. Brooklyn Investment Group purchased a new stake in United Therapeutics in the third quarter valued at $33,000. Capital Performance Advisors LLP acquired a new stake in United Therapeutics during the 3rd quarter worth about $82,000. Finally, Values First Advisors Inc. purchased a new position in shares of United Therapeutics during the 3rd quarter valued at about $90,000. Hedge funds and other institutional investors own 94.08% of the company’s stock.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.